



BUREAU OF NATUROPATHIC MEDICINE
1625 North Market Blvd., Suite S-209
Sacramento, CA 95834
(916) 574-7991 – Office / (916) 574-8645 - FAX



NATUROPATHIC FORMULARY ADVISORY COMMITTEE
Meeting Minutes
September 11, 2006

**COMMITTEE MEMBERS
PRESENT:**

Peter Wannigman, Naturopathic Doctor
(Chairman)
Soram Khalsa, Medical Doctor (Vice
Chair)
Mary Hardy, Medical Doctor
Cynthia Watson, Medical Doctor
Trevor Holly Cates, Naturopathic Doctor
Michael Traub, Naturopathic Doctor
Paul Mittman, Naturopathic Doctor
Larry Woodhouse, Pharmacist

**COMMITTEE MEMBERS
ABSENT:**

Arthur Presser, Pharmacist

STAFF PRESENT:

Tonya Blood
Norine Marks
Linda Brown
Debbie Newcomer

I. Call to Order and Roll Call

Chairman Wannigman called the meeting to order. Roll call was taken and a quorum was present.

II. Approval of the August 29, 2006 Meeting Minutes

The following changes were recommended:

- 1) The word "Board" needs to be added to the phrase "Dr. Mitch Karlin, past president of the Medical" in Dr. Khalsa's report.
- 2) SCPIE needs to be spelled correctly.
- 3) Antitussives and combination antitussives were to be added to the inclusionary list.

Dr. Khalsa made a motion to approve the minutes as corrected and Dr. Hardy seconded the motion. Roll was called and the minutes were approved as corrected.

III. Chairperson's Report

Dr. Wannigman stated that the previously approved inclusionary list had a category that stated "include the entire inclusionary list of dermatologicals, except exclude methotrexate." Linda cut and pasted from the list of dermatologicals that the committee had gone through earlier so that has been included on the list for approval at this meeting. Dr. Wannigman urged the committee to make sure it reads exactly as it should before approval of the final draft.

Dr. Wannigman thanked Dr. Mittman for providing the rationale for ND prescribing. Dr. Mittman stated that he would be condensing it for the final version. The previous document which was a chapter from the textbook of Natural Medicine could be included in the Appendix, or just referenced in the report. It was concluded that it should be included in the Appendix. Linda stated that the packets to the Advisory Council were being mailed the next day so that the revisions would need to be done quickly.

Tonya stated that the Advisory Council would not be changing the reports, but could make comments on the report.

Dr. Khalsa reported that the Doctor's Company was not able to answer his questions regarding malpractice insurance and they turned it over to executive management. It will be several more weeks before he hears back from them. Dr. Khalsa will send Linda the response when he gets it and Linda will disburse it to the Committee.

It was discussed that the laws relating to homeopathic prescribing also need to be clarified but that recommendation #1 in the report already covers that. It was concluded that the report should not attempt to define homeopathic medicine as that may conflict with existing laws and cause more confusion. The recommendation should be that NDs have access to homeopathic products, which is included with the other substances in the first recommendation in the report.

The Committee discussed Dr. Traub's email on inclusionary vs. exclusionary formulary. It was suggested to revise the section to discuss the earlier approval of an exclusionary formulary, but because public safety is the primary concern, the Committee decided to go with the inclusionary formulary. Dr. Wannigman suggested including Arizona's course as part of the Appendix, but not including the exclusionary formulary in the report. Linda stated that the Bureau would always have copies of the exclusionary list if it is needed for some reason in the future. It was concluded that it would be confusing to add the 60-hour course to the Appendix, but that the section should be re-worked for the report. Linda and Tonya will do the re-write.

IV. Bureau Report

Nothing to report.

V. Discussion, Review, and Approval of IV Formulary

Dr. Wannigman stated that the Committee should stand by its earlier approval of the IV formulary that was done in July. The CNDA should get the experts to defend the formulary during the regulatory process. The substances approved are currently being used in other states without the requirement of the IV class.

Dr. Wannigman suggested changes to the July IV formulary as stated below:

Category I should include glutathione with amino acids (delete from biologicals).

Category IV electrolytes should be expanded to say electrolytes and diluents.

Category V – diluents should be removed (moving to Category IV).

Category VI – no changes.

Category VII should have the word “none” added.

Category VIII should have * after DMPS saying “subject to completion of the IV therapeutics course.”

EDTA should have note saying “subject to completion of the Chelation course.

Add number IX – Any substance in Section 3640(c)(1) that is part of an IRB.

Dr. Traub made a motion to add glutathione to the amino acids category. Dr. Cates seconded the motion. Roll was called and the motion was passed.

Dr. Cates made a motion to a) Remove diluents from category V and add it to category IV; b) add the word “none” to Botanicals; and add a Category IX to state “Any substance included in Section 3640(c)(1) that is part of an IRB.” Dr. Traub seconded the motion. Roll was called and the motion was passed.

VI. Discussion, Review, and Approval of Inclusionary Formulary

Dr. Cates made a motion to replace the IV formulary that was attached to the inclusionary list approved at the prior meeting with the IV formulary that the Committee just approved.

Dr. Watson seconded the motion. Dr. Cates asked where the IRB portion was included.

Dr. Wannigman stated that it was included in a new Category IX – any substance in Section 3640(c)(1) under an IRB. Roll was taken and the motion was passed.

Dr. Wannigman asked if the Committee wanted to include anti-diabetic agents as part of the inclusionary list. Dr. Cates made a motion to add the category anti-diabetic agents to the inclusionary list. Dr. Woodhouse seconded the motion. The motion was passed.

VII. Review of Draft Report

The committee reviewed the draft report and made suggestions.

OTC items under Dermatologicals should be removed but it cannot be done without a vote. Dr. Woodhouse will send Linda a list of the OTC items to be marked with an asterisk.

As a quorum was not present, a subcommittee motion was made by Dr. Cates to have the Bureau follow up on 1) To eliminate OTC dermatologicals on inclusionary list. 2) Eliminate refresher course for IV. Dr. Woodhouse seconded the motion. The motion passed.

VIII. Future Meeting Date(s) - ?

The Committee discussed setting a meeting date to approve the two changes noted above. A tentative date was set for Monday, September 25th at 8 a.m. or alternatively, Wednesday, September 27th at 8 a.m.

IX. Public Comment

Kevin Schunke of the Medical Board congratulated the Committee on the work it has done.

X. Adjournment

The meeting was adjourned.